ClinicalTrials.gg
RecruitingNCT06671977DMT-BolusUpdated Nov 18, 2026

Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans

A Phase 1 interventional study of DMT-Medium Dose and DMT-Low Dose in Major Depression Disorder and Depression, sponsored by Deepak C. D'Souza. Recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Deepak C. D'Souza · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Nov 18, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,715 studies in Depression with a site in United States — 579 open to participants now, 716 under way, 29 of them phase 3. Depression · United States.

Planned enrollment
1,787th of 3,322
60 · median 72
Started
2025
with 206 others
Phase 1
179 of 3,715
27 open now
Primary completion
2027-12
later than 447 of 714 live
Registered
3,334th of 3,715
by date

Among the 3,715 studies in Depression with a site in United States, this one is the 1,787th largest by planned enrollment of the 3,322 interventional ones that give a count, is one of 207 that started in 2025, is one of 179 in phase 1, reaches primary completion later than 447 of the 714 other live ones, and was the 3,334th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

579 of the 3,715 studies in Depression with a site in United States are open now. Recruiting first, the newest first:

574 more — sign in →

All 579 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,715 studies in Depression with a site in United States, or all of them as a file.
02

Study summary

The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls. We hypothesize that administration of DMT will result in decreases in depression, associated symptoms, and neuroplastic changes in depressed subjects. We expect that DMT will induce changes in neuroplasticity as indexed using electroencephalographic (EEG) measures and tasks in both depressed individuals and healthy volunteers, though to different degrees. These neuronal changes may in parallel cause changes in mood measured both in healthy and depressed subjects, which will be captured using appropriate psychometric measures of mood.

03

Conditions studied

  • Major Depression Disorder
  • Depression

Browse trials for

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Some Common Inclusion Criteria:

  1. Males and females
  2. Age 21 to 65 years
  3. between 18-35 kg/m2
  4. Willing to refrain from taking any medications not approved by the study physician
  5. Willing to refrain from using street drugs and alcohol
  6. Negative urine drug screen
  7. Willing and able to abstain from smoking throughout each test session
  8. Women who are of (WOCBP) and sexually active must be willing to practice an effective means of
  9. Willing not to drive to and from the testing session

Some Inclusion Criteria for Subjects with MDD:

  1. Diagnosed with Major Depressive Disorder (MDD)
  2. Unsatisfactory response to antidepressants
  3. Engaged in treatment for depression with a clinician and willing to continue treatment for the duration of the study
  4. Not engaged in treatment
  5. Consent to allow the research team to communicate with mental health provider.
  6. Only subjects who get support for participation in the trial from their mental health clinician will be eligible to be enrolled in the study

Some Common Exclusion Criteria:

  1. Medications that might significantly interfere with the effects of the study medications
  2. Cognitive dysfunction that could interfere with study participation
  3. Alcohol or substance use disorder
  4. Any lifetime history of hallucinogen use disorder
  5. Regular use or misuse of hallucinogens
  6. History of intolerance to perceptual altering drugs
  7. Significant blood pressure problems
  8. Pregnancy or currently breast feeding (lactation)
  9. Any unstable medical conditions
  10. Significant cardiovascular disease
  11. Significantly abnormal laboratory test results
  12. History of serotonin syndrome

Some Exclusion criteria for MDD subjects:

  1. Current primary psychiatric disorder other than MDD
  2. Medically significant condition rendering unsuitability for the study

Some Exclusion criteria for healthy controls:

  1. No current psychiatric disorder, excluding nicotine and caffeine use disorder
  2. No family history of serious mental illness (e.g., schizophrenia, bipolar disorder)

Some Inclusion criteria for healthy controls:

  1. No current DSM-5 psychiatric disorder, excluding nicotine and caffeine use disorder
  2. No lifetime use of psychiatric medication >3 months (proxy for psychiatric disorders)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    10 mg slow intravenous push (bolus) over 5 minutes and then 0.01 mg/kg/min for 55 minutes

    Low dose DMT

    Drug: DMT-Low Dose

  • Active comparator
    14 mg slow intravenous push (bolus) over 5 minutes and then 0.015 mg/kg/min for 55 minutes.

    Medium Dose DMT

    Drug: DMT-Medium Dose

  • Active comparator
    0.5 mg over 5 minutes and then 2 mg over and 55 minutes

    THC-Medium Dose

    Drug: THC-Medium Dose

  • Placebo comparator
    Placebo

    Drug: DMT-Medium Dose · Drug: DMT-Low Dose · Drug: THC-Medium Dose · Drug: THC-Low Dose

  • Active comparator
    0.1 mg slow intravenous push (bolus) over 5 minutes and then I mg over 55 minutes

    Low Dose THC

    Drug: THC-Low Dose

Interventions

  • DrugDMT-Medium Dose

    14 mg slow intravenous push (bolus) over 5 minutes and then 0.015 mg/kg/min for 55 minutes.

  • DrugDMT-Low Dose

    10 mg slow intravenous push (bolus) over 5 minutes and then 0.01 mg/kg/min for 55 minutes

  • DrugTHC-Medium Dose

    0.5 mg over 5 minutes and then 2 mg over and 55 minutes

  • DrugTHC-Low Dose

    0.1 mg slow intravenous push (bolus) over 5 minutes and then I mg over 55 minutes

06

What researchers measure

Primary outcomes

  1. Safety of Physiological indices

    Pulse oximetry will be measured continuously.

    Time frame: Time Frame: -60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration]blood pressure and heart rate will be measured before, during, and after the dosing on each test day.

  2. Psychedelic Effects

    The 30-item revised Mystical Experience Questionnaire (MEQ30) will be used to measure mystical/psychedelic experiences associated with drugs like psilocybin

    Time frame: From start Test Day Time points (Minutes): -60, +30, +120.

  3. Psychotomimetic Effects

    To capture the effects of DMT/THC/placebo on perception, thought, and sensory processing, participants will be measured using the Psychotomimetic States Inventory

    Time frame: Test Day Time points (Minutes): -60, +30, +120

  4. Anxiety

    Will be assessed using a visual analog scale that subjects will be asked to score from 0 (not at all) to 100 (worst ever) to capture anxiety.

    Time frame: Test Day Time points (Minutes): -60, +30, +120

  5. Depression

    subjects will be asked to score from 0 (not at all) to 100 (worst ever) to capture the depression.

    Time frame: From start of test day (-60), +30, and +120.

  6. Intensity of the Experience

    The Challenging Experience Questionnaire (CEQ) a 26 item likert-scale style survey will be used to provide a phenomenological profile specifically of challenging aspects of experiences with psilocybin

    Time frame: Test Day Time points (Minutes): +150 - +180

  7. Drug Reinforcing Effects

    Will be assessed with questions such as: * How likely are you to use this drug recreationally? 0 (not at all) ------------------------100 (most of all) * How much are you willing to pay for the acute effects that you experienced during the dosing session? $0-------------------$100 Shortly after resolution of effects, participants will be instructed to retroactively rate the highest effects experienced since the last time they were prompted to provide a rating.

    Time frame: Test Day Time points (Minutes): +120

  8. Tolerability of Overt Adverse Effects

    Tolerability defined by the US FDA as "the degree to which overt adverse effects can be tolerated" by a subject was assessed \[60\]. At the end of the test day, after all drug effects have worn off, participants will be asked to score 1) the overall experience on a visual analog scale \[VAS\] (0 = intolerable to 100 = well-tolerated).

    Time frame: Test Day Time points (Minutes): -60, +30, +120, 180 (end of test day)

  9. Electrophysiological

    Time frame: Resting State EEG: Will be collected the day after each dosing session. [Time Frame: -60 minutes before DMT administration until +180 minutes after DMT administration].

Secondary outcomes

  1. Expectancy Effects

    Time frame: Subjects will be tested for expectancy effects at screening, and before each dosing session.

  2. Adequacy of blinding

    Subjects will be asked to guess their treatment assignment, the degree of certainty of their guess and the reason for their guess both immediately after the psychedelic dosing session(s) and at the end of the study. Either the James' blinding index (BI) or Bang's BI, will be used to measure the adequacy of the blind.

    Time frame: Time Frame: 0; immediately after DMT administration, and +180 minutes at the end of the study

  3. Blood

    Time frame: Blood sample measurements will be repeated approximately 0, 20, 30, and 60 minutes after drug administration

  4. Changes in personality domains (NEO personality inventory)

    Time frame: [Time Frame: -60 minutes before DMT administration; 0, +30, and +60 minutes after DMT administration]

  5. Psychological Flexibility

    The Acceptance and Action Questionnaire (AAQ) is a one-factor, likert scale assessment of psychological inflexibility

    Time frame: Time Frame: +180 minutes after DMT administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.

Of 82 non-industry phase 1 interventional studies under Depression, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 61. This study's planned 32 months is close to that.

Counting every sponsor, half of 102 studies reached it within 27 months; a quarter within 11 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2024
First posted
Nov 4, 2024
StartActual
Mar 14, 2025
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: added p•••@yale.edu · •••5711. See the current contact
Nov 18, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, · West Haven, United StatesContact d•••@yale.edu · •••5711→p•••@yale.edu · •••5711
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Contact Study contact changed: added p•••@yale.edu · •••5711. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, · West Haven, United StatesContact d•••@yale.edu · •••5711→p•••@yale.edu · •••5711
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06671977
Lead sponsor
Deepak C. D'Souza
Responsible party
Deepak C. D'Souza (Deepak Cyril D'Souza, MD, Yale University) — Sponsor-investigator
First posted
Nov 4, 2024
Start date
Mar 14, 2025
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Prakash Gupta, MD
Contact
prakash.gupta@yale.edu
203-932-5711 ext. 12594
Deepak C D'Souza, MD
Contact
deepak.dsouza@yale.edu
(203) 932-5711 ext. x12594
Deepak D'Souza, MD
principal investigator · Yale University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion